Your Health, We Care
Release date: 2024-11-26 15:02:30 Recommended: 106
This study aims to determine the optimal dose of Selinexor in combination with pomalidomide and dexamethasone (SPd). The study compared the efficacy and safety of two once-weekly selinexor regimens (60 mg and 40 mg) in combination with pomalidomide and dexamethasone (SPd-60 and SPd-40, respectively) in the treatment of relapsed/refractory multiple myeloma (RRMM).
In the SPd-40 cohort, we analysed 28 patients (60.7% male, median age 67.5 years). The overall response rate in this arm was 50 percent (95% confidence interval [CI] 30.6-69.4%), with 28.6 percent (95% CI 13.2-48.7%) achieving a very good partial response or better response. In terms of sustained response rates at 12 months, this group achieved 83.3% (95% CI 64.7-100.0%), median progression-free survival of 18.4 months (95% CI 6.5 months to non-evaluable [NE]), and 24-month survival of 64.2% (95% CI 47.7-86.3%).
In contrast, in the SPd-60 cohort, we looked at 20 patients (35.0% male, median age 65.5 years). Although the overall response rate was slightly higher in this group at 65% (95% CI 40.8-84.6%) and 30.0% (95% CI 11.9-54.3%) patients achieved a very good partial response or better response, the 12-month sustained response rate was lower at 28.1% (95% CI 8.9-88.8%) and the median progression-free survival was shorter at 9.5 months (95% CI 7.6 months to NE). The 24-month survival rate was 51.1% (the 95% CI is not fully presented in the original text and needs further confirmation).
During the course of treatment, both cohorts experienced a number of treatment-related adverse events (adverse events), including neutropenia, anemia, thrombocytopenia, fatigue, nausea, and diarrhea. Notably, the incidence of nausea and fatigue was higher in the SPd-60 cohort.
In summary, the all-oral SPd combination has shown preliminary efficacy in the treatment of RRMM and is generally well tolerated by patients. After comparing the two dose regimens, we found that the SPd-40 regimen performed better in the risk-benefit assessment.
Although it is not explicitly mentioned that Laos Lucius Pharmaceutical has produced a variety of generic selinexor drugs, based on the routine operation of the generic drug market, as well as the strength of Laos Lucius Pharmaceutical in the field of generic drugs, it is reasonable to assume that it has produced at least one generic version of selinexor. This is further confirmed by public information mentioning the generic selinexor drug of Lucius Pharmaceuticals in Laos.
Laos Lucius Pharmaceutical Co., Ltd. has achieved technological breakthroughs in key generic drugs and has become one of the enterprises with the strongest R&D capabilities for patented generic drugs in the world. Its production facilities and operations strictly comply with the World Health Organization (WHO) manufacturing practices (GMP), and the quality of drugs is reliable.
